| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
Branched-chain amino acid aminotransferase 1 (BCAT1). EGR240 is a selective inhibitor of BCAT1. BCAT1 is the cytosolic isoform of branched-chain aminotransferase, which catalyzes the reversible transamination of branched-chain amino acids (BCAAs). By inhibiting BCAT1, EGR240 modulates BCAA metabolism, which has been implicated in various diseases, including cancer and inflammation.
|
|---|---|
| ln Vitro |
In vitro, EGR240 is a potent inhibitor of BCAT1, with an IC50 of 0.1-1 nM. In human macrophages, it decreases oxygen consumption and glycolysis by downregulating IRG1 expression and itaconate production. This suggests that it can modulate the metabolic and inflammatory state of immune cells.
|
| ln Vivo |
In vivo, EGR240 suppresses the production of IRG1 and itaconate in mice and contributes to a less proinflammatory transcriptome signature. This demonstrates its ability to engage its target and modulate inflammatory pathways in a living organism. It is being investigated for its potential to treat inflammatory and metabolic diseases.
|
| Enzyme Assay |
The in vitro activity of EGR240 is assessed using a BCAT1 enzyme assay. Purified BCAT1 is incubated with its substrates and varying concentrations of EGR240. The enzymatic activity is measured, and the IC50 is determined.
|
| Cell Assay |
To study its cellular effects, macrophages or other relevant cell types are treated with EGR240. The expression of IRG1 and the production of itaconate are measured by qPCR and LC-MS/MS, respectively. The effect on cellular respiration and glycolysis is assessed using a Seahorse Analyzer.
|
| Animal Protocol |
The in vivo activity of EGR240 is evaluated in mouse models of inflammation or cancer. The compound is administered orally. The levels of IRG1 and itaconate in tissues are measured, and the inflammatory transcriptome signature is analyzed.
|
| ADME/Pharmacokinetics |
EGR240 has a molecular weight of 166.15 g/mol and a molecular formula of C7H11NaO3. It is an orally active small molecule. It is soluble in water and DMSO. Specific pharmacokinetic parameters are not widely published.
|
| Toxicity/Toxicokinetics |
Specific toxicological data for EGR240 are not detailed, as it is a research compound. It is not intended for human or veterinary use. Standard laboratory safety precautions should be followed when handling the compound.
|
| References |
[1]. Papathanassiu, et al. Methods for treatment of cancer, inflammatory autoimmune disorders and bone diseases using branched-chain amino acid aminotransferase-1 (BCAT1) inhibitors. Patent. WO2012173987.
|
| Additional Infomation |
EGR240 is a research compound used to study the role of BCAT1 in various diseases. Its ability to inhibit BCAT1 and modulate itaconate production makes it a valuable tool for investigating the link between metabolism and inflammation. It has shown promise in preclinical models for improving metabolic health and supporting neuroprotection. It is not an approved drug.
|
| Molecular Formula |
C7H13NAO3
|
|---|---|
| Molecular Weight |
168.166093587875
|
| Exact Mass |
166.06
|
| CAS # |
1415683-79-2
|
| PubChem CID |
165437314
|
| Appearance |
Typically exists as solid at room temperature
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
11
|
| Complexity |
145
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC(CCC(=O)[O-])C(=O)C.[Na+]
|
| InChi Key |
QEQCTLAIARYMND-UHFFFAOYSA-M
|
| InChi Code |
InChI=1S/C7H12O3.Na/c1-5(6(2)8)3-4-7(9)10;/h5H,3-4H2,1-2H3,(H,9,10);/q;+1/p-1
|
| Chemical Name |
sodium;4-methyl-5-oxohexanoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (601.87 mM)
H2O: 100 mg/mL (601.87 mM) |
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.9464 mL | 29.7318 mL | 59.4636 mL | |
| 5 mM | 1.1893 mL | 5.9464 mL | 11.8927 mL | |
| 10 mM | 0.5946 mL | 2.9732 mL | 5.9464 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
